NRF2 Regulation Processes as a Source of Potential Drug Targets against Neurodegenerative Diseases

Biomolecules. 2020 Jun 14;10(6):904. doi: 10.3390/biom10060904.

Abstract

NRF2 acts by controlling gene expression, being the master regulator of the Phase II antioxidant response, and also being key to the control of neuroinflammation. NRF2 activity is regulated at several levels, including protein degradation by the proteasome, transcription, and post-transcription. The purpose of this review is to offer a concise and critical overview of the main mechanisms of NRF2 regulation and their actual or potential use as targets for the treatment of neurodegenerative diseases.

Keywords: KEAP1; NRF2 regulation; NRF2–ARE pathway; neurodegenerative diseases; oxidative stress.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Central Nervous System Agents* / isolation & purification
  • Central Nervous System Agents* / therapeutic use
  • Drug Discovery
  • Gene Expression Regulation / drug effects
  • Humans
  • Molecular Targeted Therapy / methods*
  • NF-E2-Related Factor 2 / antagonists & inhibitors
  • NF-E2-Related Factor 2 / drug effects
  • NF-E2-Related Factor 2 / genetics*
  • NF-E2-Related Factor 2 / metabolism*
  • Neurodegenerative Diseases / drug therapy*
  • Neurodegenerative Diseases / genetics
  • Neurodegenerative Diseases / metabolism
  • Proteolysis / drug effects

Substances

  • Central Nervous System Agents
  • NF-E2-Related Factor 2
  • NFE2L2 protein, human